Protalix BioTherapeutics Inc. (DE) Common Stock (PLX)
Stock · AMEX · Health Care
$2.62as of 10/16/2026
Price chart
Active signals
PLX Signal Track Record
How signals performed across all stocks →What PLX's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 43 | +0.9% | 53% | October 1, 2026 |
| Bollinger Band Breakout | 29 | +4.2% | 62% | August 27, 2026 |
| Bollinger Band BreakdownActive now | 16 | -0.7% | 25% | May 5, 2026 |
| 200-Day Moving Average TouchActive now | 10 | +0.4% | 50% | August 14, 2026 |
| Any 20-session window (baseline) | +1.1% | 53% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About PLX
Protalix BioTherapeutics, Inc., a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on the ProCellEx plant cell-based protein expression system. The company provides Elelyso for the treatment of Gaucher disease; and Elfabrio for the treatment of adult patients with a confirmed diagnosis of Fabry disease. It is also developing PRX-115, a…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 226
- Website
- protalix.com/
Fundamentals
- 1-day range
- $2.61$2.69
- Market cap
- $196.59M
- P/E (trailing)
- 11.27
- P/E (forward)
- 4.23
- EPS (trailing)
- $0.23
- Dividend yield
- —
- Beta
- -0.05
- Avg. volume
- 777.3K
- Dividend pay date
- December 20, 2019
How Protalix BioTherapeutics Inc. (DE) Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 18, 2026 · via SEC EDGAR / Finnhub
Forecasts
2 analyst ratings
Protalix BioTherapeutics Inc. (DE) Common Stock Competitors
Chosen by industry and closest market cap.
- PLXProtalix BioTherapeutics Inc. (DE) Common Stock$2.62▼ 2.96%Market cap $196.59MP/E 11.27$1.6$3.19
- CHRSCoherus Oncology Inc. Common Stock$0.99▼ 7.48%Market cap $195.13MP/E —$1.01$2.62
- IVVDInvivyd Inc. Common Stock$0.619▼ 7.47%Market cap $194.15MP/E —$0.5277$3.07
- DTILPrecision BioSciences Inc. Common Stock$5.77▼ 6.48%Market cap $191.45MP/E —$3.53$9.62
- ALECAlector Inc. Common Stock$1.84▼ 3.66%Market cap $203.18MP/E —$1.09$3.4
- VYGRVoyager Therapeutics Inc. Common Stock$1.9▼ 7.77%Market cap $189.12MP/E —$2.33$5.55
- OTLKOutlook Therapeutics Inc. Common Stock$0.488▼ 2.40%Market cap $181.85MP/E —$0.1611$2.54
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| PLX Protalix BioTherapeutics Inc. (DE) Common Stock | $196.59M | 11.27 | $2.62 | ▼ 2.96% | $1.6$3.19 |
| CHRS Coherus Oncology Inc. Common Stock | $195.13M | — | $0.99 | ▼ 7.48% | $1.01$2.62 |
| IVVD Invivyd Inc. Common Stock | $194.15M | — | $0.619 | ▼ 7.47% | $0.5277$3.07 |
| DTIL Precision BioSciences Inc. Common Stock | $191.45M | — | $5.77 | ▼ 6.48% | $3.53$9.62 |
| ALEC Alector Inc. Common Stock | $203.18M | — | $1.84 | ▼ 3.66% | $1.09$3.4 |
| VYGR Voyager Therapeutics Inc. Common Stock | $189.12M | — | $1.9 | ▼ 7.77% | $2.33$5.55 |
| OTLK Outlook Therapeutics Inc. Common Stock | $181.85M | — | $0.488 | ▼ 2.40% | $0.1611$2.54 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Aharon Schwartz · September 3, 2026 · Grant8.5K
- Aharon Schwartz · September 3, 2026 · Grant17.0K
- Christian Elze · September 3, 2026 · Grant8.5K
- Christian Elze · September 3, 2026 · Grant17.0K
- Zvi Shmuel Ben · September 3, 2026 · Grant8.5K
- Zvi Shmuel Ben · September 3, 2026 · Grant17.0K
- Eliot Forster · September 3, 2026 · Grant8.5K
- Eliot Forster · September 3, 2026 · Grant17.0K
- Dror Bashan · September 3, 2026 · Grant160.0K
- Dror Bashan · September 3, 2026 · Grant320.0K
- Yaron Naos · September 3, 2026 · Grant56.0K
- Yaron Naos · September 3, 2026 · Grant112.0K
- Gwen A. Melincoff · September 3, 2026 · Grant8.5K
- Gwen A. Melincoff · September 3, 2026 · Grant17.0K
- Pol F. Boudes · September 3, 2026 · Grant8.5K
Institutional Ownership
March 31, 2026
- Total shares held
- 16.52M
- Total value held
- $35.51M
- Institutional holders
- 97
- Unknown3.62M
- Unknown3.54M
- Unknown1.22M
- Unknown972.8K
- Unknown885.4K
- Unknown865.3K
- Unknown500.0K
- Unknown418.6K
- Unknown340.0K
- Unknown301.8K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 27, 2026
PLX: No direct news; broader market analyst moves noted
Recent news coverage focuses on analyst actions for other companies like Netflix and SanDisk, with no specific updates reported for Protalix BioTherapeutics. The stock currently trades within its 52-week range of $1.60 to $3.19, holding above the identified support level of $2.31. While technical signals show some divergence, the lack of company-specific headlines keeps the immediate news impact low.
PLX: No direct news; broader market analyst moves noted. Recent news coverage focuses on analyst actions for other companies like Netflix and SanDisk, with no specific updates reported for Protalix BioTherapeutics. The stock currently trades within its 52-week range of $1.60 to $3.19, holding above the identified support level of $2.31. While technical signals show some divergence, the lack of company-specific headlines keeps the immediate news impact low.